“And therefore, we expect ZYN Ultra to be able to bring some renewed momentum to the Zen brand in the coming months.”

In context

“ovations and getting those products in the market are again dependent on the FDA, PMDA process? Or is it something which is under your control? Jacek Olczak: Yes. First on this one, on innovation, of course, we follow the processes. So again, for obvious when this would come, but there is a process in the U.S., and we are following it extremely diligently I'm stating the obvious year. On the ZYN volume evolution, so yes, we are in the [indiscernible] around 5%, 6% growth. I'm talking about the last week. We'll see what is ever going to speculate. But obviously, our expectation is that ZYN Ultra is going to come with a proposal. We think it's a great product, and it's going to come with a proposal that will be matching areas of strong dynamism in the nicotine pouch market today in the U.S. And therefore, we expect ZYN Ultra to be able to bring some renewed momentum to the Zen brand in the coming months. That's our expectation. Pallav Mittal: Sure. And then just very quickly on IQOS. So looking at the growth in Europe, around 5.5%. Is it a bit lower than what you were expecting? Because historically, the growth in Europe has been high single digit, low double digits. How do you plan to accelerate that 5%, 6% growth back to the high single-digit number? Jacek Olczak: No. The growth actually is very good in Europe because if you exclude the market that has been growing recently through the flavor ban, you are at around 8% growth. So I would say, of course, in absolute level, it would be even higher because you have a higher base, but it's very much in line with what you've seen in the past quarter. So I would say if you put aside these 2 markets. And Poland is a significant one, plus a few”